Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes

Behavioural Brain Research

Volumn 220, Issue 1, 2011, Pages 30-41

  Bhutada, Pravinkumar ^a   Mundhada, Yogita ^a   Bansod, Kuldeep ^a   Tawari, Santosh ^a   Patil, Shaktipal ^a   Dixit, Pankaj ^b   Umathe, Sudhir ^c   Mundhada, Dharmendra ^a  

^a Agnihotri College of Pharmacy Wardha   (India)

^b IPS Academy   (India)

^c RTM NAGPUR UNIVERSITY   (India)

Author keywords

Berberine; Dementia; Diabetes; Donepezil; Metformin; Morris water maze; Oxidative stress; Vitamin C

Indexed keywords

ASCORBIC ACID; BERBERINE; CHOLINESTERASE; DONEPEZIL; GLUTATHIONE; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME ACTIVITY; HIPPOCAMPUS; HYPERGLYCEMIA; LEARNING DISORDER; LIPID PEROXIDATION; LONG TERM CARE; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BERBERINE; BLOOD GLUCOSE; BODY WEIGHT; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; GLUTATHIONE; HYPOGLYCEMIC AGENTS; INDANS; LIPID PEROXIDATION; MALE; MAZE LEARNING; MEMORY DISORDERS; METFORMIN; PIPERIDINES; RATS; RATS, WISTAR;

EID: 79952758240     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.022     Document Type: Article

References (77)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009, 205:265-271.
2. Aigner T.G. Pharmacology of memory: cholinergic-glutamatergic interactions. Curr Opin Neurobiol 1995, 5:155-160.
3. Appleyard M.E. Non-cholinergic functions of acetylcholinesterase. Biochem Soc Trans 1994, 22:749-755.
4. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61:661-666.
5. Beckman K.B., Ames B.N. The free radical theory of aging matures. Physiol Rev 1998, 78:547-581.
6. Bhutada P., Mundhada Y., Bansod K., Bhutada C., Tawari S., Dixit P., et al. Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats. Neurobiol Learn Mem 2010, 94:293-302.
7. Biessels G.J., Heide L.P., Kamal A. Ageing and diabetes: implications for brain function. Eur J Pharmacol 2002, 441:1-14.
8. Biessels G.J., Kamal A., Ramakers G.M., Urban I.J., Spruijt B.M., Erkelens D.W., et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 1996, 45:1259-1266.
9. Biessels G.J., Kamal A., Urban I.J., Spruijt B.M., Erkelens D.W., Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 1998, 800:125-135.
10. Biessels G.J., Kerssen A., de Haan E.H., Kappelle L.J. Cognitive dysfunction and diabetes: implications for primary care. Prim Care Diabetes 2007, 1:187-193.
11. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
12. Bolding K., Rudy J.W. Place learning in Morris water task: making the memory stick. Learning & Memory 2006, 13:278-286.
13. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 2002, 5:561-568.
14. Brands A.M., Biessels G.J., Kappelle L.J., de Haan E.H., de Valk H.W., Algra A., et al. Cognitive functioning and brain MR1 in patients with type 1 and type 2 diabetes mellitus: a comparative study. Dement Geriatr Cogn Disord 2007, 23:343-350.
15. Cameron N.E., Eaton S.E.M., Cotter M.A., Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1450-1458.
16. Cukierman T., Gerstein H.C., Williamson J.D. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. J Diabet 2005, 48:12-19.
17. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
18. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
19. Ellman G.L., Courtney K.D., Abdres V, Feather-stone R.M. A new rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 88-95.
20. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and tress activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
21. Fukui K., Onodera K., Shinkai T., Suzuki S., Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann NY Acad Sci 2001, 928:168-175.
22. Gallagher M., Colombo P.J. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995, 5:161-168.
23. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000, 23:542-549.
24. Gu Y., Zhang Y., Shi X., Li X., Hong J., Chen J., et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010, 81:766-772.
25. Hasanein P., Shahidi S. Effects of combined treatment with vitamins C and E on passive avoidance learning and memory in diabetic rats. Neurobiol Learn Mem 2010, 93:472-478.
26. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998, 105:412-422.
27. Huang L., Shi A., He F., Li X. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem 2010, 18(3):1244-1251.
28. Imanshahidi M., Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008, 22:999-1012.
29. Kamal A., Biessels G.J., Duis S.E., Gispen W.H. Learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: interaction of diabetes and ageing. Diabetologia 2000, 43:500-506.
30. Kim D.K., Lee K.T., Baek N.I., Kim S.H., Park H.W., Lim J.P., et al. Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa. Arch Pharm Res 2004, 27:1127-1131.
31. Kim H.B., Jang M.H., Shin M., Lim B.V., Kim Y.P., Kim K.J., et al. Treadmill exercise increase cell proliferation in dentate gyrus of rats with streptozotocin-induced diabetes. J Diabetes Complications 2003, 17:23-29.
32. Knopman D.S., Boland L.L., Mosley T., Howard G., Liao D., Szklo M., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48.
33. Kuhad A., Sethi R., Chopra K. Lycopene attenuates diabetes-associated cognitive decline in rats. Life Sci 2008, 83:128-134.
34. Kulkarni S.K., Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010, 24:317-324.
35. Kumagai A.K. Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab Res Rev 1999, 15:261-273.
36. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
37. Leng S.H., Lu F.E., Xu L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004, 4:496-502.
38. Li L., Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007, 56:384-402.
39. Liu W., Liu P., Tao S., Deng Y., Li X., Lan T., et al. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys 2008, 475:128-134.
40. Mankovsky B.N., Metzger B.E., Molitch M.E., Biller J. Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications 1996, 10:228-242.
41. Manschot S.M., Biessels J.G., Cameron N.E., Cotter M.A., Kamal A., Kappelle L.J., et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res 2003, 966:274-282.
42. Mastrocola R., Restivo F., Vercellinatto I., Danni O., Brignardello E., Aragno M., et al. Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J Endocrinol 2005, 187:37-44.
43. McCall A.L. Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol 2004, 490:147-158.
44. McNamara R.K., Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Brain Res Rev 1993, 59:193-204.
45. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 2005, S26-S30. 26S.
46. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
47. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
48. Northam E., Rankins D., Cameron F.J. Therapy insight: the impact of type 1 diabetes on brain development and function. Nat Clin Pract Neurol 2006, 2:78-86.
49. Northam E.A., Rankins D., Lin A., Wellard R.M., Pell G.S., Finch S.J., et al. Central nervous system functions in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 2009, 32:445-450.
50. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
51. Peng W.H., Hsieh M.T., Wu C.R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997, 74:261-266.
52. R̈oosen P., Nawroth P.P., King G., M̈oller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association, and the German diabetes society. Diabetes Metab Res Rev 2001, 17:189-212.
53. Reynolds R.M., Strachan M.W., Labad J., Lee A.J., Frier B.M., Fowkes F.G., et al. Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2010, 33:714-720.
54. Rovet J.F. Diabetes. Pediatric neuropsychology: research, theory, and practice 2000, 336-365. Guilford Press, New York. K.W. Yeates, M.D. Ris, H.G. Taylor (Eds.).
55. Ryan C.M., Freed M.I., Rood J.A., Cobitz A.R., Waterhouse B.R., Strachan M.W. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006, 29:345-351.
56. Sánchez-Chávez G., Salceda R. Effect of streptozotocin-induced diabetes on activities of cholinesterases in the rat retina. IUBMB Life 2000, 49:283-287.
57. Schmatz R., Mazzanti C.M., Spanevello R., Stefanello N., Gutierres J., Corrêa M., et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 2009, 610:42-48.
58. Sima A.A.F., Kamiya H., Lia Z.G. Insulin C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 2004, 490:187-197.
59. Somfai G.M., Knippel B., Ruzicska E., Stadler K., Tóth M., Salacz G., et al. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats. Neurochem Int 2006, 48:746-752.
60. Strachan M.W.J., Frier B.M., Deary I.J. Type 2 diabetes and cognitive impairment. Diabet Med 2003, 20:1-2.
61. Tang L.Q., Wei W., Chen L.M., Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006, 108:109-115.
62. Tiwari V., Kuhad A., Bishnoi M., Chopra K. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav 2009, 93:183-189.
63. Tuzcu M., Baydas G. Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol 2006, 537:106-110.
64. Umathe S.N., Kochar N.I., Jain N.S., Dixit P.V. Gastrointestinal dysfunction in diabetic rats relates with a decline in tissue l-arginine content and consequent low levels of nitric oxide. Nitric Oxide 2009, 20:129-133.
65. van den Berg E., Kloppenborg R.P., Kessels R.P.C., Kappelle L.J., Biessels G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim et Biophys Acta 2009, 1792:470-481.
66. Vitek M.P., Bjattacharya K., Glendening M.J., Stopa E., Vlassara H., Bucala R., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA 1994, 91:4766-4770.
67. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997, 46:S19-S37.
68. Wang C., Li J., Lu X., Zhang M., Song Y., Chen L., et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol 2009, 620:131-137.
69. Whiteley C.G., Daya S. Protein ligand interactions Part 5: isoquinoline alkaloids as inhibitors of acetylcholinesterase from Electrophorus electricus. J Enzyme Inhib 1995, 9:285-294.
70. Wong T.Y., Klein R., Sharrett A.R., Couper D.J., Klein B.E.K., Liao D.P., et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 2002, 288:67-74.
71. Wrighten S.A., Piroli G.G., Grillo C.A., Reagan L.P. A look inside the diabetic brain: contributors to diabetes-induced brain aging. Biochim et Biophys Acta 2009, 1792:444-453.
72. Yin J., Xing H., Ye J Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008, 57:712-717.
73. Yu Y., Liu L., Wang X., Liu X., Liu X., Xie L., et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 2010, 79:1000-1006.
74. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008, 93:2559-2565.
75. Zhou J., Zhou S., Tang J., Zhang K., Guang L., Huang Y., et al. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 2009, 606:262-268.
76. Zhou X., Zeng X., Kong H., Sun X. Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett 2008, 447:31-36.
77. Zhu F., Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 2006, 7:78.